Wikiwand AI

Fukutin-related protein

Mammalian protein found in Homo sapiens From Wikipedia, the free encyclopedia

Fukutin-related protein (FKRP) is also known as FKRP_HUMAN, LGMD2I, MDC1C, MDDGA5, MDDGB5, and MDDGC5. FKRP can be located in the brain, cardiac muscle and skeletal muscle, and in cells it is found in the Golgi apparatus.[5] Fukutin is expressed in the mammalian retina and is located in the Golgi complex of retinal neurons.[6]

AliasesFKRP, LGMD2I, MDC1C, MDDGA5, MDDGB5, MDDGC5, fukutin related protein, LGMDR9, FKTR
External IDsOMIM: 606596; MGI: 2447586; GeneCards: FKRP
End46,776,988 bp[1]
Quick facts FKRP, Identifiers ...
FKRP
Identifiers
AliasesFKRP, LGMD2I, MDC1C, MDDGA5, MDDGB5, MDDGC5, fukutin related protein, LGMDR9, FKTR
External IDsOMIM: 606596; MGI: 2447586; GeneCards: FKRP
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001039885
NM_024301

NM_173430
NM_001358846

RefSeq (protein)

NP_001034974
NP_077277

NP_775606
NP_001345775

Location (UCSC)Chr 19: 46.75 – 46.78 MbChr 7: 16.54 – 16.55 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse
Close

The genomic location of the FKRP gene is on chromosome 19. FKRP is a ribitol-5-phosphate (enzyme) glycosyltransferase, which means this enzyme helps create glycosidic linkages to an acceptor. In glycosylation of α-dystroglycan (sugar chain) it adds a ribitol-5-phosphate onto the M3 core O-mannosylation of α-dystroglycan to create O-linked mannosylation.[7] Without this linkage α-dystroglycan will not function properly, this can cause issues with the cytoskeleton, and extracellular matrix. In skeletal muscles the α-dystroglycan helps stabilize and protect muscle fibers, in the brain it directs movement of nerve cells.[8] This could be caused by mutations that binds ribitol-5-phosphate to the α-dystroglycan incorrectly. These mutations have been found to be associated with congenital muscular dystrophy, dystroglycanopathies, and Walker-Warburg syndrome.[9] The severity of these diseases are correlated to the amount of mutations occurring. Possible therapy options for FKRP mutations include small molecules, gene delivery, and cell therapy.

In 2024, a deep mutational scanning was conducted, which generated functional scores for all possible single nucleotide variants of the FKRP coding sequence.[10]

See also

References

Related Articles

Timelines

Top Qs

Fact Checks